Pyxis Oncology (PYXS) to Release Earnings on Thursday

Pyxis Oncology (NASDAQ:PYXS) is expected to release its earnings data before the market opens on Thursday, March 20th. Analysts expect Pyxis Oncology to post earnings of ($0.32) per share for the quarter.

Pyxis Oncology Stock Performance

Shares of NASDAQ:PYXS opened at $1.16 on Tuesday. The stock has a market capitalization of $68.98 million, a price-to-earnings ratio of -1.13 and a beta of 1.11. Pyxis Oncology has a one year low of $0.99 and a one year high of $6.18. The company has a 50-day simple moving average of $1.37 and a 200-day simple moving average of $2.42.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Pyxis Oncology stock. Bank of America Corp DE boosted its stake in shares of Pyxis Oncology, Inc. (NASDAQ:PYXS) by 20.3% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 53,745 shares of the company’s stock after buying an additional 9,062 shares during the quarter. Bank of America Corp DE owned 0.09% of Pyxis Oncology worth $84,000 as of its most recent filing with the Securities and Exchange Commission. Hedge funds and other institutional investors own 39.09% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts recently issued reports on the stock. HC Wainwright reissued a “buy” rating and set a $5.00 price target (down from $7.00) on shares of Pyxis Oncology in a report on Friday, December 20th. Royal Bank of Canada reissued an “outperform” rating and set a $8.00 price target (down from $10.00) on shares of Pyxis Oncology in a report on Friday, December 20th. Finally, William Blair cut shares of Pyxis Oncology from an “outperform” rating to a “market perform” rating in a report on Thursday, November 21st. One investment analyst has rated the stock with a hold rating and five have given a buy rating to the company. According to MarketBeat, Pyxis Oncology has a consensus rating of “Moderate Buy” and an average price target of $9.20.

Pyxis Oncology Company Profile

Pyxis Oncology, Inc, a clinical stage company, engages in the development of therapeutics to treat cancers. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors.